I

    Incannex Healthcare Ltd ADR (IXHL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $3.35
    -0.29 (-7.97%)

    Market Cap: $43.55M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    86%(6/7)
    Avg Surprise
    +25.87%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Jun 30, 2026
    EPS Consensus$-1.00
    Range$-1.00 - $-1.00
    1 analysts
    Revenue Consensus
    $-309000
    Range$-309000 - $-309000
    2 analysts
    Period ending Sep 30, 2026
    EPS Consensus$-0.51
    Range$-0.51 - $-0.51
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-0.51
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Sep 26EST
    		-$-0.51---
    Jun 26EST
    		-$-1.00---
    Mar 26
    Reported May 15
    		$-0.49$-0.84+41.67%Beat-104.2%
    Dec 25
    Reported Feb 13
    		$-0.85$-0.93+8.60%Beat+94.5%
    Sep 25
    Reported Nov 14
    		$-0.92N/A+94.91%Beat+93.1%
    Jun 25
    Reported Sep 29
    		$-0.78$-0.45-73.33%Miss-91.6%
    Mar 25
    Reported May 15
    		$-0.24$-0.46+47.83%Beat+36.8%
    Dec 24
    Reported Feb 14
    		$-15.56$-20.43+23.84%Beat-4612.3%
    Sep 24
    Reported Nov 14
    		$-13.41$-21.48+37.57%Beat-744900.0%
    Jun 24
    Reported Jun 30
    		$-0.41N/AN/ABeat-5400.0%
    Mar 24
    Reported May 15
    		$-0.38N/AN/ABeat-295.0%
    Dec 23
    Reported Mar 1
    		$-0.33N/AN/ABeat-
    Sep 23
    Reported Dec 1
    		$-0.00N/AN/ABeat-
    Dec 22
    Reported Mar 30
    		$-0.01N/AN/ABeat-
    Sep 22
    Reported Sep 30
    		$-0.10N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.10EV/EBITDA-5.13x
    Price/FCF-2.33xFCF Yield-43.00%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-117.20%ROIC-50.28%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio41.56xQuick Ratio41.56x
    Trading Statistics
    Beta2.81Avg Volume91.69K
    52-Week High$20.3152-Week Low$2.49

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.57
    SMA 20$3.37
    SMA 50$3.32
    SMA 200$6.04
    EMA 10$3.53
    EMA 20$3.43
    EMA 50$3.42
    EMA 200$6.45

    MACD

    Line: 0.10Signal: 0.08Hist: 0.02

    ADX

    ADX: 24.8+DI: 22.8-DI: 20.5

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down16.0
    PSAR$3.93

    Bollinger Bands

    Upper Band$3.85
    Lower Band$2.89
    %B Position2856%(Upper)
    Band Width0.48

    RSI (14-Day)

    Neutral
    47.8

    Momentum Oscillators

    Stoch %K55.3
    Stoch %D66.1
    Williams %R-69.4
    ROC (10d)1.1%
    Momentum0.04
    CCI (20d)22.8
    MFI (14d)66.0

    Volatility Measures

    ATR (14d)$0.19(5.8%)
    StdDev (20d)0.24
    Hist Vol44.7%(High)

    Volume Flow

    VWAP$3.44
    OBV2.9B
    AD Line4563.9B
    CMF (20d)0.064

    Volume Metrics

    Avg Vol (20d)88.4K
    Vol Ratio0.9x
    VWMA (20d)$3.37

    Pivot Points

    R3$3.96
    R2$3.87
    R1$3.76
    Pivot Point$3.67
    S1$3.55
    S2$3.46
    S3$3.35

    Advanced Oscillators

    TSI20.85
    Ultimate Osc41.7
    KST108.62

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$0$0$0$66,616$0$12,000$74,000$12,000$0$0$0$0
    Cost of Revenue$0$0$0$179,816$0$0$0$17,000$0$0$0N/A
    Gross Profit$0$0$0N/A$0$12,000$74,000$12,000$0$0$0N/A
    Operating Expenses$4.05M$7.00M$6.79M$7.53M$5.00M$5.02M$6.33M$9.76M$7.42M$7.98M$4.89MN/A
    R&D$321,000$2.28M$1.12M$3.70M$2.73M$1.41M$2.90M$4.36M$3.28M$2.64M$2.61M$0
    SG&A$3.73M$4.71M$5.67M$3.83M$2.27M$3.60M$3.43M$5.41M$4.14M$5.34M$2.28M$0
    Operating Income$-4,048,000$-6,995,000$-6,794,000$-7,528,000$-5,003,000$-5,004,000$-6,254,000$-9,751,000$-7,415,000$-7,983,000$-4,892,000N/A
    Interest Income$-38,000$11,000$6,000$58,000$4,000$0$0$40,000$75,000$20,000$71,000$0
    Interest Expense$0$-5,000$-5,000$534,000$1.13M$143,000$-28,000$0$0$0$0$0
    Income Before Tax$-3,883,000$-6,521,000$-6,407,000$-31,603,000$-3,968,000$-5,894,000$-5,420,000$-6,431,000$-6,031,000$-5,241,000$-726,000$0
    Income Tax Expense$0$0$0$0$0$0$0$30,000$0$0$0$0
    Net Income$-3,883,000$-6,521,000$-6,407,000$-31,603,000$-3,968,000$-5,894,000$-5,420,000$-6,461,000$-6,031,000$-5,241,000$-726,000N/A
    EBITDA$-3,780,000$-6,478,000$-6,352,000$-31,066,000$-2,851,000$-5,625,000$-5,384,000$-6,409,000$-6,089,000$-5,234,000$-785,000N/A
    EBIT$-3,845,000$-6,537,000$-6,418,000$-31,127,000$-2,846,000$-5,751,000$-5,448,000$-6,471,000$-6,106,000$-5,246,000$-797,000$-4,540,998
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IXHL

    News

    IXHL Q4'26 Earnings: revenue estimate is 0 USD

    Incannex Healthcare Inc. (IXHL) is scheduled to release its Q4'26 earnings on September 2nd, with an estimated revenue of $0 USD and an anticipated EPS of ($0.14) USD. The article also provides a table showing historical and estimated revenue and EPS figures, highlighting past revenue and EPS surprises.

    TradingView•8/26/26•
    Neutral

    Incannex doses first patient in sleep apnea drug trial By Investing.com

    Incannex Healthcare Inc. (NASDAQ:IXHL) has dosed its first patient in the DReAMzz Phase 2 dose-optimization study for IHL-42X, an oral drug candidate for obstructive sleep apnea. This follows positive results from its Phase 2 RePOSA study, which showed significant reductions in the apnea-hypopnea index. IHL-42X has Fast Track designation from the FDA, aiming to accelerate its development and review process.

    Investing.com Nigeria•8/25/26•
    Bullish

    Incannex doses first patient in sleep apnea drug trial

    Incannex Healthcare Inc. (NASDAQ:IXHL) has dosed its first patient in the Phase 2 DReAMzz dose-optimization study for IHL-42X, an oral drug candidate for obstructive sleep apnea. This follows positive Phase 2 RePOSA study results and Fast Track designation from the FDA. The DReAMzz study aims to determine the optimal dose for Phase 3 development, evaluating sleep-related measures and patient-reported outcomes.

    Investing.com•8/25/26•
    Bullish

    Incannex Healthcare Doses First Patient in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

    Incannex Healthcare has announced the dosing of the first patient in its DReAMzz Phase 2 study for IHL-42X, an oral combination therapy designed to treat obstructive sleep apnea (OSA). This follows positive results from the previous Phase 2 RePOSA study, which demonstrated significant reductions in the apnea-hypopnea index and a strong safety profile. The DReAMzz study aims to optimize the dose for future development, and IHL-42X has received FDA Fast Track designation, highlighting its potential to address a significant unmet medical need for OSA.

    Quiver Quantitative•8/25/26•
    Bullish

    Sleep-apnea candidate showed up to 83% fewer breathing interruptions; Incannex doses first patient

    Incannex Healthcare announced that the first patient has been dosed in its DReAMzz Phase 2 study for IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea (OSA). This milestone follows positive results from the earlier Phase 2 RePOSA study, where IHL-42X showed statistically significant reductions in apnea-hypopnea index (AHI) up to 83%, and it has received FDA Fast Track designation. The DReAMzz study aims to optimize the dose for IHL-42X and support its progression to a Phase 3 development program.

    Stock Titan•8/25/26•
    Bullish

    Frequently Asked Questions About IXHL

    Does IXHL pay dividends?
    Incannex Healthcare Ltd ADR (IXHL) does not currently pay a regular dividend.
    What is IXHL's market cap?
    Incannex Healthcare Ltd ADR (IXHL) has a market capitalization of $43.55M with a current stock price of $3.35.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In